Diagnosis and management of aspergillosis in the Netherlands: A national survey

Pieter P.A. Lestrade, Jacques F. Meis, Jan P. Arends, Martha T. van der Beek, Els de Brauwer, Karin van Dijk, Sabine C. de Greeff, Pieter Jan Haas, Caspar J. Hodiamont, Ed J. Kuijper, Tjalling Leenstra, Anouk E. Muller, Astrid M.L. Oude Lashof, Bart J. Rijnders, Eveline Roelofsen, Wouter Rozemeijer, Mathijs Tersmette, Elizabeth M. Terveer, Cees M. Verduin, Maurice J.H.M. WolfhagenWillem J.G. Melchers, Paul E. Verweij

Research output: Contribution to journalArticleAcademicpeer-review

39 Citations (Scopus)


A survey of diagnosis and treatment of invasive aspergillosis was conducted in eight University Medical Centers (UMCs) and eight non-academic teaching hospitals in the Netherlands. Against a background of emerging azole resistance in Aspergillus fumigatus routine resistance screening of clinical isolates was performed primarily in the UMCs. Azole resistance rates at the hospital level varied between 5% and 10%, although rates up to 30% were reported in high-risk wards. Voriconazole remained first choice for invasive aspergillosis in 13 out of 16 hospitals. In documented azole resistance 14 out of 16 centres treated patients with liposomal amphotericin B.

Original languageEnglish
Pages (from-to)101-107
Number of pages7
Issue number2
Publication statusPublished - 1 Feb 2016


  • Aspergillosis
  • Azole resistance
  • Treatment

Cite this